BWX Technologies R&D increased by 7.6% to $4.10M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 103.7%, from $2.01M to $4.10M. Over 4 years (FY 2021 to FY 2025), R&D shows an upward trend with a 5.8% CAGR.
Higher spending signals a commitment to innovation and future product launches, whereas significant cuts may indicate a shift toward short-term profitability.
Research and development expenses represent the costs incurred to discover new products, improve existing technologies,...
Highly comparable across pharmaceutical and medical device peers, where R&D intensity is a key metric for long-term valuation.
research_and_development| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $3.51M | $2.87M | $1.57M | $2.95M | $2.61M | $1.43M | $2.55M | $2.20M | $2.60M | $1.16M | $1.66M | $1.49M | $1.27M | $2.08M | $2.64M | $2.01M | $4.57M | $3.48M | $3.81M | $4.10M |
| QoQ Change | — | -18.1% | -45.4% | +88.3% | -11.6% | -45.4% | +78.5% | -13.4% | +17.7% | -55.5% | +43.4% | -10.1% | -14.7% | +63.7% | +26.7% | -23.6% | +126.8% | -23.8% | +9.5% | +7.6% |
| YoY Change | — | — | — | — | -25.5% | -50.3% | +62.3% | -25.4% | -0.6% | -18.9% | -34.9% | -32.4% | -51.0% | +80.0% | +59.0% | +35.1% | +259.2% | +67.2% | +44.5% | +103.7% |
| Segment | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|
| Government Operations | $1.45M | $1.92M | $2.08M | $2.91M | $2.96M |
| Commercial Operations | $562.00K | $2.64M | $1.40M | $904.00K | $1.14M |
| Total | $2.01M | $4.57M | $3.48M | $3.81M | $4.10M |